Initial clinical experience with AZD5718, a novel once daily oral 5-lipoxygenase activating protein (FLAP) inhibitor, intended for patients with coronary artery disease
Event:
ESC Congress 2017
Topic:
Drug therapy
Session:
Best Posters in new targets in cardiovascular drug assessment
